> ## Documentation Index
> Fetch the complete documentation index at: https://mintlify.com/Ge0frey/nullgraph/llms.txt
> Use this file to discover all available pages before exploring further.
# Why NullGraph
> Understanding the publication bias crisis and how NullGraph creates economic incentives for sharing negative results.
# Why NullGraph
The scientific community has a hidden crisis: **95% of null results never see the light of day**. This isn't a minor inefficiency -- it's a systemic failure that distorts science, wastes billions in research funding, and slows medical breakthroughs.
## The publication bias crisis
### The 95% problem
When researchers run experiments that produce negative or null results -- experiments that disprove a hypothesis or find no significant effect -- those results overwhelmingly go unpublished. Journals favor positive findings, and researchers have no career incentive to document failures.
This creates four cascading problems:
### 1. Publication bias
Journals overwhelmingly favor positive results, creating a distorted scientific record. When only successful experiments are published, the literature overstates the efficacy of treatments, the strength of correlations, and the reproducibility of findings.
**Real-world impact:**
* Meta-analyses become unreliable
* Drug efficacy appears higher than reality
* Failed approaches appear unexplored
Publication bias means the scientific literature is not a representative sample of actual research -- it's a systematically skewed subset that overrepresents success.
### 2. Wasted replication
Researchers unknowingly repeat experiments that have already been proven to fail. Without access to negative results, labs around the world duplicate dead-end approaches.
**The cost:**
* Billions in research funding spent re-failing
* Years of researcher time on known-bad paths
* Opportunity cost of experiments not run
Every unpublished null result is a landmine waiting to be stepped on by the next researcher who tries the same approach.
### 3. Lost investment
Research institutions, pharmaceutical companies, and public funding agencies invest heavily in experiments. When those experiments produce null results, the investment produces zero public value -- the data sits in filing cabinets or on local hard drives.
**The waste:**
* Public funding produces private knowledge
* Institutional knowledge dies when researchers leave
* No return on investment for failed experiments
### 4. Zero incentive
Researchers have **no career, financial, or reputational reason** to publish negative findings:
* No journal will accept it (or only low-tier journals)
* No citations or h-index boost
* No grant reviewers care about your failures
* No promotion committees reward documenting dead ends
The current system actively punishes researchers for doing the right thing.
## How NullGraph solves this
NullGraph creates **economic incentives** for sharing null results by making them **permanent, discoverable, and valuable**.
### Permanence: On-chain Null Knowledge Assets
Every null result becomes a **Null Knowledge Asset (NKA)** -- a permanent, immutable record stored on Solana. NKAs include:
* Full experimental metadata (hypothesis, methodology, outcomes)
* Statistical rigor (p-value, sample size)
* Data provenance (SHA-256 hash linking to off-chain datasets)
* Researcher attribution (wallet address)
Once minted, an NKA exists forever. It can't be taken down, edited retroactively, or lost when a lab closes.
NKAs use Program Derived Addresses (PDAs) with seeds `["null_result", researcher_pubkey, specimen_number]` ensuring deterministic, collision-free addressing.
### Discoverability: Dashboard and registry
All NKAs are instantly searchable through the NullGraph Dashboard. Researchers and BioDAOs can:
* Browse the full NKA registry
* Filter by researcher, date, or statistical significance
* Link directly to Solana Explorer for on-chain verification
* Access full experimental details
No paywalls, no journal subscriptions, no access restrictions.
### Value: Bounty marketplace
NullGraph creates a **two-sided marketplace** where:
**Demand side (BioDAOs, pharma, researchers):**
* Post bounties describing specific null results they need
* Escrow BIO tokens as rewards
* Review submissions and approve matching NKAs
**Supply side (researchers):**
* Submit NKAs to matching bounties
* Receive BIO token payouts on approval (97.5% after protocol fee)
* Build reputation through successful bounty fulfillments
Bounties use PDA-controlled vaults with CPI token transfers via the SPL Token Interface, ensuring funds are only released on explicit creator approval.
### Economic alignment
For the first time, researchers have a **financial reason** to document and share negative results:
1. **Direct compensation** through bounty payouts
2. **Reputational credit** through on-chain attribution
3. **Future optionality** -- NKAs minted today can match bounties posted months later
4. **Public good incentive** -- protocol fees fund ongoing development
## Real-world use cases
### BioDAO knowledge acquisition
A longevity-focused BioDAO needs to know which senolytic compounds have already been tested and failed in mouse models. Instead of funding duplicate experiments, they post a 10,000 BIO bounty for null results on specific compounds.
Result: **Instant access to failed experiments, saving months and \$500K in lab costs.**
### Pharmaceutical due diligence
A biotech company is considering licensing a drug candidate. Before committing, they post bounties for any null results on related mechanisms of action.
Result: **Risk mitigation through access to negative data that would never appear in journals.**
### Academic meta-analysis
A research group conducting a systematic review needs unpublished negative trials to correct for publication bias. They post bounties for null RCT results in their domain.
Result: **More accurate meta-analyses reflecting true effect sizes, not just published successes.**
### Lab knowledge transfer
A PI retires and their lab's unpublished negative results would be lost forever. Before closing, they mint NKAs for all failed experiments.
Result: **Institutional knowledge preserved on-chain, available for future researchers.**
## Why Solana + BIO tokens?
### Solana: Speed and cost
* **Sub-second finality** -- NKAs appear instantly
* **Low transaction fees** -- minting an NKA costs \~\$0.00025
* **High throughput** -- scales to millions of NKAs
* **Composability** -- other protocols can build on NullGraph
### BIO tokens: Aligned incentives
* **Shared ecosystem** with Bio Protocol's DeSci infrastructure
* **Liquidity** -- researchers can immediately convert payouts
* **Governance potential** -- future DAO participation
* **Network effects** -- more BioDAOs using BIO = more bounty demand
NullGraph uses the SPL Token Interface (`anchor-spl/token_interface`) ensuring compatibility with any SPL-compliant token, not just BIO.
## The path forward
NullGraph doesn't just solve publication bias -- it creates a **new primitive for scientific knowledge**. Null Knowledge Assets are:
* **Programmable** -- smart contracts can reference and reward NKAs
* **Composable** -- other protocols can index, verify, or aggregate NKAs
* **Tradeable** (future) -- NKAs could have secondary markets for high-value negative results
* **Verifiable** -- decentralized verification networks could stake on NKA validity
### Future enhancements
* **BioDAO-funded bounties** -- DAOs programmatically funding bounties via governance
* **Knowledge graph indexing** -- decentralized indexers building NKA relationship graphs
* **Community verification** -- reputation-weighted validation of NKA claims (Pending → Verified → Disputed status transitions)
* **NFT extensions** -- NKAs as tradeable knowledge assets with royalty splits
## The bottom line
Science produces two kinds of results: discoveries and non-discoveries. Journals only publish one. NullGraph publishes both.
By making null results permanent, discoverable, and economically valuable, NullGraph fixes the 95% problem and creates a more honest, efficient scientific ecosystem.
Ready to mint your first Null Knowledge Asset? Check out the [Quickstart guide](/quickstart) or explore the [Program reference](/api-reference/program-overview).